Delving into the Latest Updates on JY-231 with Synapse

Overview

Basic Info

Drug Type

CAR-T

Synonyms

JY 231, JY231

Target

CD19

Action

inhibitors

Mechanism

CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), Cell replacements

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesNeoplasms+ [2]

Active Indication

Systemic Lupus ErythematosusRefractory B Acute Lymphoblastic LeukemiaCD19 positive B-Cell Lymphoma+ [4]

Inactive Indication-

Originator Organization

Guangdong Provincial People's Hospital

Active Organization

Shenzhen Genocury Biotech Co., Ltd.920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaGuangdong Provincial People's Hospital

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B-cell Acute Lymphoblastic Leukemia (B-ALL).

Start Date31 Mar 2025

Sponsor / Collaborator

Zhejiang University

NCT06887985

/ Not yet recruitingNot ApplicableIIT

An Early Exploratory Clinical Study of the Safety, Tolerability, and Initial Efficacy of JY231 Injection for the Treatment of Refractory Autoimmune Diseases (ADs)

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with Refractory Autoimmune Diseases (ADs). It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of Refractory Autoimmune Diseases (ADs).

Start Date31 Mar 2025

Sponsor / Collaborator

Zhejiang University

NCT06890065

/ Not yet recruitingNot Applicable

An Early-Phase Exploratory Clinical Study of JY231 Injection in Relapsed/Refractory B-Cell Lymphoma/Leukemia: Safety, Tolerability, and Preliminary Efficacy

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma /leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma / leukemia.

Start Date01 Mar 2025

Sponsor / Collaborator

Shenzhen Genocury Biotech Co., Ltd.

100 Clinical Results associated with JY-231

Login to view more data

100 Translational Medicine associated with JY-231

Login to view more data

100 Patents (Medical) associated with JY-231

Login to view more data

100 Deals associated with JY-231

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Systemic Lupus Erythematosus	Phase 2	China	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China	09 Oct 2024
Refractory B Acute Lymphoblastic Leukemia	Phase 1	China	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China	20 Jun 2024
CD19 positive B-Cell Lymphoma	Phase 1	China	Guangdong Provincial People's Hospital	18 Aug 2023
Marginal Zone B-Cell Lymphoma	Clinical	China	Shenzhen Genocury Biotech Co., Ltd.	01 Mar 2025
Mediastinal large B-cell lymphoma	Clinical	China	Shenzhen Genocury Biotech Co., Ltd.	01 Mar 2025
Pre B-cell acute lymphoblastic leukemia	Clinical	China	Shenzhen Genocury Biotech Co., Ltd.	01 Mar 2025
T-cell/histiocyte rich large B-cell lymphoma	Clinical	China	Shenzhen Genocury Biotech Co., Ltd.	01 Mar 2025